NCT02629848View on ClinicalTrials.gov

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

March 31, 2015

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Motesanib

Motesanib (AMG 706) 5 x 25 mg tablets

DRUG

Placebo

Motesanib placebo-matching tablets

DRUG

Paclitaxel

Paclitaxel IV

DRUG

Carboplatin

Carboplatin IV

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY